Thrombolytic therapy with intravenous rt-PA in mild acute stroke patients: Analysis of sits registry data

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA20020UM" target="_blank" >RIV/61988987:17110/17:A20020UM - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jns.2017.08.1782" target="_blank" >http://dx.doi.org/10.1016/j.jns.2017.08.1782</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jns.2017.08.1782" target="_blank" >10.1016/j.jns.2017.08.1782</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Thrombolytic therapy with intravenous rt-PA in mild acute stroke patients: Analysis of sits registry data

Popis výsledku v původním jazyce

Mild ischemic stroke severity is the most common reason for exclusion from thrombolytic treatment at the time of emergency department evaluation because of worry of a poor outcome and a potential risk of intracerebral hemorrhage. Previous studies suggest that up to 43% of ischemic stroke patients are not treated with intravenous recombinant tissue plasminogen activator (rt-PA) because of mild or rapidly improving symptoms. Also, the use of rt-PA is not recommended in current medical license and guidelines for these ischemic stroke patients because of an uncertain risk-benefit ratio. In contrast, recent studies demonstrate that up to one third of these patients dies or are permanently disabled. study objective was to evaluate safety and effectiveness of intravenous thrombolysis (IVT) in mild ischemic stroke patients with National Institutes of Health Stroke Scale score (NIHSS) less than 5

Název v anglickém jazyce

Thrombolytic therapy with intravenous rt-PA in mild acute stroke patients: Analysis of sits registry data

Popis výsledku anglicky

Mild ischemic stroke severity is the most common reason for exclusion from thrombolytic treatment at the time of emergency department evaluation because of worry of a poor outcome and a potential risk of intracerebral hemorrhage. Previous studies suggest that up to 43% of ischemic stroke patients are not treated with intravenous recombinant tissue plasminogen activator (rt-PA) because of mild or rapidly improving symptoms. Also, the use of rt-PA is not recommended in current medical license and guidelines for these ischemic stroke patients because of an uncertain risk-benefit ratio. In contrast, recent studies demonstrate that up to one third of these patients dies or are permanently disabled. study objective was to evaluate safety and effectiveness of intravenous thrombolysis (IVT) in mild ischemic stroke patients with National Institutes of Health Stroke Scale score (NIHSS) less than 5

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

JOURNAL OF THE NEUROLOGICAL SCIENCES

ISBN

—

ISSN

0022-510X

e-ISSN

1878-5883

Počet stran výsledku

1

Strana od-do

632-632

Název nakladatele

ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS

Místo vydání

AMSTERDAM, NETHERLANDS

Místo konání akce

Kyoto, JAPAN

Datum konání akce

1. 1. 2017

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

000427450302204